Gelsomino, Fabio
Azienda Ospedaliero-Universitaria di Modena
3 papers on CoChatORCID 0000-0001-7979-4795
Most cited papers
- Verified
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 2,079
- Verified
Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial
Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Cited by 280
- Verified
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 270
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free